These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


113 related items for PubMed ID: 3209305

  • 1. Immunoscintigraphy with 131I-labelled monoclonal antibodies HMFG2 and HMFG1 F(ab')2 versus abdominal CT scan in the detection of residual disease in ovarian cancer patients.
    Pectasides D, Pateniotis K, Tzimis L, Trapalli X, Natsis P, Arapantoni P, Taylor-Papadimitriou J, Epenetos A, Koutsiouba P, Athanassiou A.
    Int J Cancer Suppl; 1988; 3():83-8. PubMed ID: 3209305
    [Abstract] [Full Text] [Related]

  • 2. Immunoscintigraphy with 131I-labelled HMFG2 and HMFG1 F(ab')2 in the pre-operative detection of clinical and subclinical lymph node metastases in breast cancer patients.
    Athanassiou A, Pectasides D, Pateniotis K, Tzimis L, Natsis P, Lafi A, Arapantoni P, Koutsiouba P, Taylor-Papadimitriou J, Epenetos A.
    Int J Cancer Suppl; 1988; 3():89-95. PubMed ID: 3209306
    [Abstract] [Full Text] [Related]

  • 3. Immunoscintigraphy with 131I-labelled H17E2 monoclonal antibody compared with conventional lymphangiography and computed tomography in the detection of metastases in patients with testicular germ cell tumours.
    Pectasides D, Vonorta P, Tsialta-Salihou A, Pateniotis K, Barbounis V, Kayianni H, Arapantoni P, Taylor-Papadimitriou J, Epenetos A, Koutsiouba P.
    Br J Cancer Suppl; 1990 Jul; 10():74-7. PubMed ID: 2166553
    [Abstract] [Full Text] [Related]

  • 4. Comparative study of RIS with the 131I-OC 125 F(ab')2 Mab and CT scan prior to second look operation for ovarian cancer.
    Papazefkos V, Michalas S, Papantoniou V, Datseris J, Athanasiadis P, Akrivos T, Leonti A, Xygakis A, Aravantinos D.
    Eur J Obstet Gynecol Reprod Biol; 1990 Dec; 37(3):271-7. PubMed ID: 2227070
    [Abstract] [Full Text] [Related]

  • 5. Radioimmunoscintigraphy using monoclonal antibodies to CEA, CA 19-9 and CA 125.
    Baum RP, Lorenz M, Hottenrott C, Albrecht M, Senekowitsch R, Happ J, Hertel A, Spitz J, Hör G.
    Int J Biol Markers; 1988 Dec; 3(3):177-84. PubMed ID: 3230337
    [Abstract] [Full Text] [Related]

  • 6. Immunoscintigraphy of recurrences of gynecologic carcinomas.
    Chatal JF, Fumoleau P, Saccavini JC, Thedrez P, Curtet C, Bianco-Arco A, Chetanneau A, Peltier P, Kremer M, Guillard Y.
    J Nucl Med; 1987 Dec; 28(12):1807-19. PubMed ID: 3500284
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Immunolymphoscintigraphy and immunoscintigraphy of ovarian and fallopian tube cancer using F(ab')2 fragments of monoclonal antibody OC 125.
    Lehtovirta P, Kairemo KJ, Liewendahl K, Seppälä M.
    Cancer Res; 1990 Feb 01; 50(3 Suppl):937s-940s. PubMed ID: 2297745
    [Abstract] [Full Text] [Related]

  • 10. Immunoscintigraphy with 131I or 111In labelled OC 125 F(ab')2 fragments in patients with ovarian carcinoma.
    Jiménez-Vicioso A, Torres M, Jiménez-Heffernan A, Grana MD, Latre JM, Llamas JM, Carreras JL, Mateo A.
    Int J Biol Markers; 1990 Feb 01; 5(4):159-65. PubMed ID: 2093731
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Distribution of radiolabeled monoclonal antibody MX35 F(ab')2 in tissue samples by storage phosphor screen image analysis: evaluation of antibody localization to micrometastatic disease in epithelial ovarian cancer.
    Finstad CL, Lloyd KO, Federici MG, Divgi C, Venkatraman E, Barakat RR, Finn RD, Larson SM, Hoskins WJ, Humm JL.
    Clin Cancer Res; 1997 Aug 01; 3(8):1433-42. PubMed ID: 9815829
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. 123I radioiodinated antibody imaging of occult ovarian cancer.
    Epenetos AA, Shepherd J, Britton KE, Mather S, Taylor-Papadimitriou J, Granowska M, Durbin H, Nimmon CC, Hawkins LR, Malpas JS.
    Cancer; 1985 Mar 01; 55(5):984-7. PubMed ID: 3881163
    [Abstract] [Full Text] [Related]

  • 15. [Preparation of F(ab')2 fragment of monoclonal antibody COC166-9 and its experimental study of radioimmunoimaging for ovarian carcinoma].
    Li X, Qian H, Feng J.
    Zhonghua Fu Chan Ke Za Zhi; 1997 Mar 01; 32(3):152-5. PubMed ID: 9596889
    [Abstract] [Full Text] [Related]

  • 16. Monoclonal antibody targeting of ovarian carcinoma.
    Kosmas C, Kalofonos HP, Hird V, Epenetos AA.
    Oncology; 1998 Mar 01; 55(5):435-46. PubMed ID: 9732222
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparison of therapeutic efficacy and host toxicity of two different 131I-labelled antibodies and their fragments in the GW-39 colonic cancer xenograft model.
    Blumenthal RD, Sharkey RM, Kashi R, Goldenberg DM.
    Int J Cancer; 1989 Aug 15; 44(2):292-300. PubMed ID: 2759735
    [Abstract] [Full Text] [Related]

  • 19. Immunoscintigraphy of ovarian cancer with indium-111-labeled OV-TL 3 F(ab')2 monoclonal antibody.
    Massuger LF, Kenemans P, Claessens RA, Verheijen RH, Schijf CP, Strijk SP, Poels LG, van Hoesel RG, Corstens FH.
    J Nucl Med; 1990 Nov 15; 31(11):1802-10. PubMed ID: 2230993
    [Abstract] [Full Text] [Related]

  • 20. Kinetics and tissue distribution of the radiolabeled chimeric monoclonal antibody MOv18 IgG and F(ab')2 fragments in ovarian carcinoma patients.
    Buist MR, Kenemans P, den Hollander W, Vermorken JB, Molthoff CJ, Burger CW, Helmerhorst TJ, Baak JP, Roos JC.
    Cancer Res; 1993 Nov 15; 53(22):5413-8. PubMed ID: 8221680
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 6.